{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:57:51Z","timestamp":1794351471404,"version":"4.9.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ijantimicag.2020.106220","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T13:01:10Z","timestamp":1604667670000},"page":"106220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":111,"title":["Long-acting drugs and formulations for the treatment and prevention of HIV infection"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4495-5349","authenticated-orcid":false,"given":"Charles","family":"Flexner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9819-7651","authenticated-orcid":false,"given":"Andrew","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3539-7867","authenticated-orcid":false,"given":"Marco","family":"Siccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Swindells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106220_bib0001","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1089\/aid.2018.0214","article-title":"Qualitative consumer research on acceptance of long-acting pre-exposure prophylaxis products among men having sex with men and medical practitioners in the United States","volume":"34","author":"Calder","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0002","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s10461-016-1565-9","article-title":"Preferences for long-acting pre-exposure prophylaxis (PrEP), daily oral PrEP, or condoms for HIV prevention among U.S. men who have sex with men","volume":"21","author":"Greene","year":"2017","journal-title":"AIDS Behav"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183521","article-title":"Willingness of community-recruited men who have sex with men in Washington, DC to use long-acting injectable HIV pre-exposure prophylaxis","volume":"12","author":"Levy","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114700","article-title":"High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy","volume":"9","author":"Meyers","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0005","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2217\/nnm.12.214","article-title":"Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients","volume":"8","author":"Williams","year":"2013","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0006","article-title":"Women's perspectives on and experiences with long-acting injectable anti-retroviral therapy in the United States and Spain: the potential role of gender in patient preferences","author":"Mantsios","year":"2019","journal-title":"ID Week 2019"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0007","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/QAI.0000000000001896","article-title":"Interest of youth living with HIV in long-acting antiretrovirals","volume":"80","author":"Weld","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0008","series-title":"14th International Conference on HIV Treatment and Prevention Adherence","article-title":"Acceptability and preferences for long-acting antiretroviral formulations among people living with HIV infection","author":"Dandachi","year":"2019"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190487","article-title":"Experiences with long acting injectable ART: a qualitative study among PLHIV participating in a Phase II study of cabotegravir\u00a0+\u00a0rilpivirine (LATTE-2) in the United States and Spain","volume":"13","author":"Kerrigan","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/25787489.2019.1661696","article-title":"Patient-reported tolerability and acceptability of cabotegravir\u2009+\u2009rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study","volume":"20","author":"Murray","year":"2019","journal-title":"HIV Res Clin Pract"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0011","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/QAI.0000000000000301","article-title":"GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects","volume":"67","author":"Spreen","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0012","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0013","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/COH.0000000000000474","article-title":"Rilpivirine long-acting for the prevention and treatment of HIV infection","volume":"13","author":"Ferretti","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0014","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0015","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0016","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1074\/jbc.M114.614305","article-title":"Derivatives of mesoxalic acid block translocation of HIV-1 reverse transcriptase","volume":"290","author":"Bernatchez","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0017","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1128\/AAC.05036-14","article-title":"Oral administration of the nucleoside EFdA (4\u02b9-ethynyl-2-fluoro-2\u02b9- deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque","volume":"59","author":"Stoddart","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0018","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1093\/jac\/dkx280","article-title":"M184I\/V substitutions and E138K\/M184I\/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA","volume":"72","author":"Oliveira","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0019","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01058-18","article-title":"Extended-duration MK-8591-eluting implant as a candidate for HIV treatment and prevention","volume":"62","author":"Barrett","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0020","series-title":"Proceedings of the 10th IAS Conference on HIV Science (IAS 2019)","article-title":"First-in-human trial of MK-8591-eluting implants demonstrates concentrations suitable for HIV prophylaxis for at least one year","author":"Matthews","year":"2019"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0021","series-title":"Abstracts of the 24th Conference on Retroviruses and Opportunistic Infections (CROI 2017)","article-title":"Discovery of novel potent HIV capsid inhibitors with long-acting potential","author":"Winston","year":"2017"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0022","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1093\/jac\/dkx208","article-title":"Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients","volume":"72","author":"Perrier","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0023","series-title":"Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"Safety and PK of subcutaneous GS-6207, a novel HIV-1 capsid inhibitor","author":"Sagar","year":"2010"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0024","series-title":"Proceedings of the 10th IAS Conference on HIV Science (IAS 2019)","article-title":"Safety and antiviral activity over 10 days following a single dose of subcutaneous GS-6207, a first-in-class, long-acting HIV capsid inhibitor in people living with HIV","author":"Daar","year":"2019"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0025","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/COH.0000000000000475","article-title":"Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection","volume":"13","author":"Cohen","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0026","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV antibody VRC01 on viral rebound after treatment interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(19)30181-X","article-title":"Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial","volume":"6","author":"Gaudinski","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0029","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1126\/science.aan8630","article-title":"Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques","volume":"358","author":"Xu","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0030","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.addr.2016.02.003","article-title":"Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: insights for applications in HIV therapy","volume":"103","author":"Owen","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0031","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/COH.0000000000000591","article-title":"Long-acting implants to treat and prevent HIV infection","volume":"15","author":"Weld","year":"2020","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0032","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41467-017-02294-6","article-title":"Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy","volume":"9","author":"Kirtane","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0033","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jconrel.2018.11.002","article-title":"Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension","volume":"292","author":"McCrudden","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0034","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1021\/ci400001u","article-title":"Quantitative structure\u2013activity relationship models of clinical pharmacokinetics: clearance and volume of distribution","volume":"53","author":"Gombar","year":"2013","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/1062936X.2010.548351","article-title":"QSARs for PBPK modelling of environmental contaminants","volume":"22","author":"Peyret","year":"2011","journal-title":"SAR QSAR Environ Res"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0036","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40262-014-0227-1","article-title":"Physiologically based pharmacokinetic modelling to inform development of intramuscular long-acting nanoformulations for HIV","volume":"54","author":"Rajoli","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0037","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejpb.2019.09.011","article-title":"Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK","volume":"144","author":"Rajoli","year":"2019","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0038","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/infdis\/jiy726","article-title":"Predicting drug\u2013drug interactions between rifampicin and long-acting cabotegravir and rilpivirine using physiologically based pharmacokinetic modeling","volume":"219","author":"Rajoli","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0039","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/psp4.12200","article-title":"A mathematical model to predict HIV virological failure and elucidate the role of lymph node drug penetration","volume":"6","author":"Sanche","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0040","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.xphs.2020.01.016","article-title":"Integration of computational and experimental approaches to elucidate mechanisms of first-pass lymphatic drug sequestration and long-acting pharmacokinetics of the injectable triple-HIV drug combination TLC-ART 101","volume":"109","author":"Perazzolo","year":"2020","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0041","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1186\/s12889-019-7276-1","article-title":"Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa","volume":"19","author":"Cheng","year":"2019","journal-title":"BMC Public Health"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0042","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00007-19","article-title":"Activity of a long-acting injectable bedaquiline formulation in a paucibacillary mouse model of latent tuberculosis infection","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0043","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0044","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41467-017-02603-z","article-title":"Long-acting injectable atovaquone nanomedicines for malaria prophylaxis","volume":"9","author":"Bakshi","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(19)30342-X","article-title":"Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV","volume":"7","author":"Bollinger","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2020.106220_bib0046","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMra1810477","article-title":"Global elimination of chronic hepatitis","volume":"380","author":"Thomas","year":"2019","journal-title":"N Engl J Med"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920304313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920304313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:38:30Z","timestamp":1760377110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920304313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0924857920304313"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106220","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-acting drugs and formulations for the treatment and prevention of HIV infection","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106220","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106220"}}